Voyager Therapeutics' (VYGR) Outperform Rating Reiterated at Wedbush

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a report issued on Wednesday,Benzinga reports.

A number of other research firms also recently weighed in on VYGR. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, March 3rd. Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a "buy" rating and a $12.00 target price for the company. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $14.86.

Remove Ads

Voyager Therapeutics Stock Down 4.2 %

Shares of NASDAQ:VYGR traded down $0.17 during midday trading on Wednesday, reaching $3.90. 367,455 shares of the company were exchanged, compared to its average volume of 479,087. Voyager Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $10.66. The stock has a fifty day simple moving average of $4.83 and a two-hundred day simple moving average of $5.82. The firm has a market cap of $213.04 million, a PE ratio of 5.49 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. During the same quarter in the previous year, the business earned $1.25 earnings per share. As a group, analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company's stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 10,778 shares of company stock valued at $58,548 in the last quarter. Company insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Empowered Funds LLC boosted its holdings in shares of Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after buying an additional 2,278 shares during the period. Rhumbline Advisers boosted its holdings in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after buying an additional 2,354 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock worth $378,000 after buying an additional 2,400 shares during the period. Picton Mahoney Asset Management boosted its holdings in shares of Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after buying an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the period. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.